Results 141 to 150 of about 7,774 (200)

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, Volume 13, Issue 55, 5 October 2026.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source

DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1-CDK4/6 Complex Protein Degradation. [PDF]

J Am Chem Soc
Zheng R, Prasad A, Satyabola D, Xu Y, Roy S, Yan Y, Šulc P, Yan H.   +7 more
europepmc   +1 more source

Imine Reductase‐Mediated Regio‐ and Stereoselective Reductive Amination of Diamines

ChemCatChem, Volume 18, Issue 19, 14 October 2026.
Imine reductases (IREDs) have been employed as biocatalysts for the regioselective modification of diamines via reductive amination. The use of racemic diamines resulted in both regio‐ and enantio‐selective reductive amination via kinetic resolution. The application of this methodology has been demonstrated on a preparative scale by the synthesis of a ...
Arnau Rué Casamajo, Yuqi Yu, Lucian Pirvu, Christian Schnepel, Simon J. Charnock, Francesco Falcioni, Martin A. Hayes, Nicholas J. Turner   +7 more
wiley   +1 more source

Identification of a Proteolysis-Targeting-Chimera that Addresses Activated Checkpoint Kinase-1 Reveals its Non-Catalytic Functions in Tumor Cells. [PDF]

Angew Chem Int Ed Engl
Ashry R, Abdelsalam M, Hausen J, Hieber C, Zeyn Y, Sarnow AC, Schmidt M, Najafi S, Oehme I, Bros M, Chen JX, Dejung M, Sippl W, Krämer OH.   +13 more
europepmc   +1 more source

Computational strategies to address therapeutic resistance in estrogen receptor‐positive breast cancer: A narrative review of molecular docking, molecular dynamics simulations, and emerging therapeutic targets

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Computational drug discovery integrates molecular docking, molecular dynamics simulations, and translational clinical targeting to identify next‐generation therapeutics that overcome endocrine resistance in ER‐positive breast cancer. Combined with multi‐omics, artificial intelligence, and biomarker‐guided precision oncology, these approaches accelerate
Emmanuel Ifeanyi Obeagu, Yaregal Asres
wiley   +1 more source

PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. [PDF]

Target Oncol
Hamilton EP, Jeselsohn RM, Vahdat LT, Hurvitz SA.   +3 more
europepmc   +1 more source

Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Bioactive peptides (BAPs) derived from host, marine, insect, plant and synthetic sources share cationic, amphipathic structures adopting α‐helical, β‐sheet or cyclic conformations. These features underlie anti‐cancer effects, including membrane disruption, apoptosis and cell‐cycle arrest, anti‐metastatic activity, reduced invasion and migration, and ...
Najwa Doha, Richa Gill, Sergio Crovella, Haissam Abou‐Saleh, Sahar Isa Da'as   +4 more
wiley   +1 more source

SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody–drug conjugate (ADC) targeting the cell‐surface pseudokinase ROR1 is effective in RT patients.
Matilde Micillo, Beatrice Pirajno, Francesco Edoardo Vallone, Victor Navarro‐Tableros, Elisabetta Bolli, Valentina Griggio, Brian J. Lannutti, Katti A. Jessen, Tiziana Vaisitti, Silvia Deaglio   +9 more
wiley   +1 more source

DNA-Programmable Protein Degradation: Dynamic Control of Proteolysis-Targeting Chimera Activity via DNA Hybridization and Strand Displacement. [PDF]

JACS Au
Kashyap D, Haider S, Milne TA, Booth MJ.
europepmc   +1 more source

Targeting the PI3K/Akt Signaling Pathway: A Promising Therapeutic Strategy to Reduce Cancer Mortality and Overcome Chemoresistance

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims The phosphatidylinositol 3‐kinase (PI3K)/Akt signaling pathway is a central regulator of cellular properties that are essential for cancer progression, including cellular growth, survival, metabolism, and angiogenesis. Dysregulated PI3K/Akt signaling, often caused by genetic alterations in PIK3CA, loss of PTEN, or the ...
Md Mohiuddin
wiley   +1 more source